Patient NAME : Mr.
GAUTAM SINGH CLIENT NAME : DHANVI CHERITABLE LAB
Age/Gender : 38 Y 0 M 0 D /Male Sample Collection : 19/Mar/2025 06:48AM
Visit ID : HVD68419 Registration : 18/Mar/2025 05:39PM
Barcode NO : U1205262 Reported : 19/Mar/2025 10:42AM
Ref Doctor :DHANVI LAB
CLIENT CODE :AMB02
DEPARTMENT OF HAEMATOLOGY
Test Name Result Unit Bio. Ref. Range Method
Complete blood count with Esr (CBC)
Hemoglobin(HB) 13.1 g/dl 13.0-18.0 Photometric/Non
Cyanmethemoglobin
Method
Total Leucocytes Count(WBC) 7,930 Cells/Cumm 4000-10500 Automated optical Flow
cytometry/Manual
Total Count and Differential Count
Neutrophils 65 % 40-80 Impedance/microscopy
Lymphocytes 30 % 20-40 Impedance/microscopy
Eosinophils 3 % 01-06 Impedance/microscopy
Monocytes 2 % 02-10 Impedance/microscopy
Basophils 0 % 00-01 Impedance/microscopy
Absolute Neutrophil Count 5,154 x10^3 2000-8000 Automated Calculated
Cells/uL
ABSOLUTE LYMPHOCYTE COUNT 2,379 x10^3 1000-3000 Automated Calculated
Cells/uL
Absolute Eosinophil Count(AEC) 238 Cells/cumm 20-500 Automated Calculated
ABSOLUTE MONOCYTE COUNT 159 x10^3 200-1000 Automated Calculated
Cells/uL
Mean Cell Haemoglobin (MCH) 28.5 pg 27-32 Automated Calculated
MCHC 29.5 g/dl 31.5-34.5 Automated/Calculated
Erythrocyte count (RBC COUNT) 4.60 million/cmm 3.8-4.8 Impedance
Packed Cell Volume(Hematocrit) 44.30 % 36-46 Cell Counter
Mean Cell Volume (MCV) 96.70 fL 83-101 Automated/Calculated
Red Cell Distribution Width (RDW)- 56.20 fL 35-56 Automated/Calculated
SD
This is an electronically authenticated report. Report printed date: 19-Mar-2025 02:45 PM,
Note: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.
Page 1 of 7
Patient NAME : Mr.GAUTAM SINGH CLIENT NAME : DHANVI CHERITABLE LAB
Age/Gender : 38 Y 0 M 0 D /Male Sample Collection : 19/Mar/2025 06:48AM
Visit ID : HVD68419 Registration : 18/Mar/2025 05:39PM
Barcode NO : U1205262 Reported : 19/Mar/2025 10:42AM
Ref Doctor :DHANVI LAB
CLIENT CODE :AMB02
DEPARTMENT OF HAEMATOLOGY
Test Name Result Unit Bio. Ref. Range Method
Red Cell Distribution Width (RDW)- 15.00 % 11.5-14.5 Automated/Calculated
CV
Platelet Count 1.80 Lakh/cumm 1.50 - 4.50 Impedance/microscopy
Plateletcrit (PCT) 0.20 % 0.2-0.5 Automated Optical
Flowcytometer
Platelet-Large Cell Count (P-LCC) 100.00 lakh/cmm 40-100 Automated Calculated
Platelet large cell ratio (P-LCR) 54.60 % 11.9-66.9 Automated/Calculated
Platelet Distribution Width (PDW-CV) 16.30 % 9.00-17.00 Automated/Calculated
Platelet Distribution Width (PDW-SD) 28.70 0-25 Automated/Calculated
Platelet-to-Lymphocyte Ratio(PLR) 74.70 36.63-149.13 Automated/Calculated
Erythrocytes Sedimentation Rate 10.00 mm/1st hr 0-10 Westergren
(ESR)
Interpretation - There have been some reports of WBC and platelet counts being lower in venous blood than in capillary blood
samples,although still within these reference ranges. Macrocytic Anemia can have low platelet count Note : The result obtained
relate only to the sample given/ received & tested. A single test result is not always indicative of a disease, it has to be correlated
with clinical data for interpretation.
This is an electronically authenticated report. Report printed date: 19-Mar-2025 02:45 PM,
Note: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.
Page 2 of 7
Patient NAME : Mr.GAUTAM SINGH CLIENT NAME : DHANVI CHERITABLE LAB
Age/Gender : 38 Y 0 M 0 D /Male Sample Collection : 19/Mar/2025 06:48AM
Visit ID : HVD68419 Registration : 18/Mar/2025 05:39PM
Barcode NO : U1205261 Reported : 19/Mar/2025 08:38AM
Ref Doctor :DHANVI LAB
CLIENT CODE :AMB02
DEPARTMENT OF BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Range Method
GLUCOSE- FASTING (FBS)
Glucose- Fasting 114.70 mg/dl Non Diabetic: 70-106 GOD-POD,END
mg/dL POINT
Prediabetes: 106-125
mg/dL
Diabetes Mellitus: 126 or
higher
INTERPRETATION:
ncreased In
Diabetes Mellitus
Stress (e.g., emotion, burns, shock, anesthesia)
Acute pancreatitis
Chronic pancreatitis
Wernicke encephalopathy (vitamin B1 deficiency)
Effect of drugs (e.g. corticosteroids, estrogens, alcohol, phenytoin, thiazides)
CLINICAL COMMENT :
Elevated glucose levels (Hyperglycemia) are mostly associated with Diabetes mellitus but may be observed in case of
neoplasms, hyperthyroidism, pancreatic and adrenocortical disorders. Hyperglycemia can also be due to effect of drugs
(e.g. corticosteroids, estrogens, alcohol, phenytoin, thiazides). Decreased glucose levels (Hypoglycemia) may occur due
increased insulin secretion, prolonged fasting or liver disease.
This is an electronically authenticated report. Report printed date: 19-Mar-2025 02:45 PM,
Note: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.
Page 3 of 7
Patient NAME : Mr.GAUTAM SINGH CLIENT NAME : DHANVI CHERITABLE LAB
Age/Gender : 38 Y 0 M 0 D /Male Sample Collection : 19/Mar/2025 06:48AM
Visit ID : HVD68419 Registration : 18/Mar/2025 05:39PM
Barcode NO : U1205263 Reported : 19/Mar/2025 08:38AM
Ref Doctor :DHANVI LAB
CLIENT CODE :AMB02
DEPARTMENT OF BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Range Method
LIVER FUNCTION TEST
Total Bilirubin 0.59 mg/dL 0.0-1.0 DCA
Conjugated (D. Bilirubin) 0.15 mg/dL 0.0-0.2 DCA
Unconjugated ( I.D.Bilirubin) 0.44 mg/dl 0.0-0.8 Calculated
Alkaline Phosphatase 157.85 U/L 53-128 IFCC,KINETIC
Alanine Aminotransferase(ALT/SGPT) 119.50 U/L <40 IFCC
Aspartate Transaminase (AST/SGOT) 63.50 U/L 0.0-37.0 IFCC
Total Protein 7.40 gm/dl 6.0-8.0 Biuret
Serum Albumin 4.10 g/dl 3.7-5.3 Bromocresol Green
(BCG)
Seum Globulin 3.30 g/dl 2.3-3.6 Calculated
Albumin/Globulin Ratio 1.24 Ratio 1.0-2.1 Calculated
Comments - Liver Function Tests (LFTs) are group of tests that can be used to detect the presence of liver disease, distinguish
among different types of liver disorders, gauge the extent of known liver damage, and monitor the response to treatment. Most
liver diseases cause only mild symptoms initially, but these diseases must be detected early. Some tests are associated with
functionality (e.g., albumin), some with cellular integrity (e.g., transaminase), and some with conditions linked to the biliary tract
(gamma-glutamyl transferase and alkaline phosphatase). Conditions with elevated levels of ALT and AST include hepatitis A,B ,C
,paracetamol toxicity etc.Several biochemical tests are useful in the evaluation and management of patients with hepatic
dysfunction. Note : The result obtained relate only to the sample given/ received & tested. A single test result is not always
indicative of a disease, it has to be correlated with clinical data for interpretation.
This is an electronically authenticated report. Report printed date: 19-Mar-2025 02:45 PM,
Note: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.
Page 4 of 7
Patient NAME : Mr.GAUTAM SINGH CLIENT NAME : DHANVI CHERITABLE LAB
Age/Gender : 38 Y 0 M 0 D /Male Sample Collection : 19/Mar/2025 06:48AM
Visit ID : HVD68419 Registration : 18/Mar/2025 05:39PM
Barcode NO : U1205263 Reported : 19/Mar/2025 08:38AM
Ref Doctor :DHANVI LAB
CLIENT CODE :AMB02
DEPARTMENT OF BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Range Method
KFT+ELECTROLYTES (SERUM)
Blood Urea 17.28 mg/dL 14-40 GLDH KINETIC
METHOD
Blood Urea NItrogen(BUN) 8.07 mg/dl 5-25 Calculated
Serum Creatinine 0.96 mg/dl 0.7-1.4 JAFFE-Kinetic
Bun/Creatinine Ratio 8.41 6-23 Calculated
Serum Uric Acid 6.70 mg/dL 3.4-7.0 PAP
Calcium 8.75 mg/dl 8.6-10.2 ARSENAZO III
Sodium 141.30 mmol/L 135-155 ISE Direct
Potassium 4.36 mmol/L 3.5-5.0 ISE Direct
Chloride 102.50 mmol/L 95-108 ISE Direct
COMMENTS- Urea is a non-proteinous nitrogen compound formed in the liver from ammonia as an end product of protein metabolism. Increased levels are found in acute renal failure, chronic
glomerulonephritis, congestive heart failure, decreased renal perfusion, diabetes, excessive protein ingestion, gastrointestinal (GI) bleeding, hyperalimentation, hypovolemia, ketoacidosis, muscle wasting
from starvation, neoplasms, pyelonephritis, shock, urinary tract obstruction, nephrotoxic drugs. Decreased levels are seen in inadequate dietary protein, low-protein/high-carbohydrate diet, malabsorption
syndromes, pregnancy, severe liver disease and certain drugs.Creatinine is catabolic product of creatinine phosphate, which is excreted by filtration through the glomerulus and by tubular secretion.
Creatinine clearance is an acceptable clinical measure of glomerular filtration rate (GFR). Increased levels are seen in acute/chronic renal failure, urinary tract obstruction, hypothyroidism, nephrotoxic drugs,
shock, dehydration, congestive heart failure, diabetes. Decreased levels are found in muscular dystrophy. BUN is directly related to protein intake and nitrogen metabolism and inversely related to the rate of
excretion of urea. Blood urea nitrogen (BUN) levels reflect the balance between the production and excretion of urea. Increased levels are seen in renal failure (acute or chronic), urinary tract obstruction,
dehydration, shock, burns, CHF, GI bleeding, nephrotoxic drugs. Decreased levels are seen in hepatic failure, nephrotic syndrome, cachexia (low-protein and high-carbohydrate diets). BUN/Creatinineratio
is decreased in acute tubular necrosis, advanced liver disease, low protein intake and following hemodialysis. BUN/Creatinine ratio is increased in dehydration, GI bleeding, and increased catabolism. Uric
acid levels show diurnal variation. The level is usually higher in the morning and lower in the evening. Increased levels are seen in starvation, strenuous exercise, malnutrition, or lead poisoning, gout,
renal disorders, increased breakdown of body cells in some cancers (including leukemia, lymphoma, and multiple myeloma) or cancer treatments, hemolytic anemia, sickle cell anemia, or heart failure, pre-
eclampsia, liver disease (cirrhosis), obesity, psoriasis, hypothyroidism, low blood levels of parathyroid hormone (PTH), certain drugs, foods that are very high in purines - such as organ meats, red meats,
some seafood and beer. Decreased levels are seen in liver disease, Wilson's disease, Syndrome of inappropriate ant diuretic hormone (SIADH), certain drugs.Electrolyte profile(* profile is not a scope of nabl)
disturbance showing Extreme fatigue. A prolonged bout of diarrhea or vomiting. Signs of dehydration. Unexplained confusion, muscle cramps, numbness or tingling.certain electrolyte is too high, the
kidney might try to release more of it in your urine. Electrolyte imbalances can cause problems with many
This is an electronically authenticated report. Report printed date: 19-Mar-2025 02:45 PM,
Note: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.
Page 5 of 7
Patient NAME : Mr.GAUTAM SINGH CLIENT NAME : DHANVI CHERITABLE LAB
Age/Gender : 38 Y 0 M 0 D /Male Sample Collection : 19/Mar/2025 06:48AM
Visit ID : HVD68419 Registration : 18/Mar/2025 05:39PM
Barcode NO : U1205263 Reported : 19/Mar/2025 08:38AM
Ref Doctor :DHANVI LAB
CLIENT CODE :AMB02
DEPARTMENT OF BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Range Method
LIPID PROFILE
Total Cholesterol 115.80 mg/dl Desirable:<200 Spectrophotometry
Borderline:200-239
High risk:>240
Triglycerides 119.80 mg/dl Normal:<150 PAP
BorderLine:150-199
High:200-499
Very High:>500
Cholesterol-HDL 53.26 mg/dl Low:<35 Direct measure-PEG
Optimal:35-60
Desirable:>80
Cholesterol-L D L (Direct) 38.58 mg/dl Normal:<100~Borderline Calculated
High:130-159~Very
High:>190
Cholesterol- V L D L 23.96 mg/dl 7-40 Calculated
Total Cholesterol /HDL Ratio 2.17 <6 Calculated
LDL / HDL Ratio 0.72 Ratio 0.0-3.5 Calculated
COMMENTS: Measurements in the same patient can show physiological & analytical variations. Three serial samples 1week
apart are recomended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.As per NCEP guidelines, all adults above the
age of 20 years should be screened for lipid status.NCEP Identifies elevated Triglycerides as an independent risk factor for
Coronary Heart Disease (CHD) .ATP III guidelines uses LDL Cholesterol as the primary target for Cholesterol lowering therapy.
Note that major risk factors can modify LDL goals
This is an electronically authenticated report. Report printed date: 19-Mar-2025 02:45 PM,
Note: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.
Page 6 of 7
Patient NAME : Mr.GAUTAM SINGH CLIENT NAME : DHANVI CHERITABLE LAB
Age/Gender : 38 Y 0 M 0 D /Male Sample Collection : 19/Mar/2025 06:48AM
Visit ID : HVD68419 Registration : 18/Mar/2025 05:39PM
Barcode NO : U1205263 Reported : 19/Mar/2025 08:27AM
Ref Doctor :DHANVI LAB
CLIENT CODE :AMB02
DEPARTMENT OF HORMONE ASSAYS
Test Name Result Unit Bio. Ref. Range Method
THYROID PROFILE I (T3, T4, TSH)
Tri-Iodothyronine Total (T3) 72 ng/dL >18 yrs: 60 -181 Chemiluminescence
Pregnancy
1st Trimester: 81-91
2nd &3rd trimester:100-
260
Thyroxine Total (T4) 5.10 µg/dL 4.82-15.65 Chemiluminescence
TSH - ULTRASENSITIVE 9.80 µIU/mL 0.35-5.50 Chemiluminescence
INTERPRETATION:
Serum T3, T4 and TSH are the measurements form three components of thyroid screening panel and are useful in diagnosing various disorders of thyroid gland
function., Primary hyperthyroidism is accompanied by elevated serum T3 and T4 values along with depressed TSH levels., Primary hypothyroidism is accompanied by
depressed serum T3 and T4 values and elevated serum TSH levels., Normal T4 levels accompanied by high T3 levels are seen in patients with T3 thyrotoxicosis. Slightly
elevated T3 levels may be found in pregnancy and in estrogen therapy while depressed levels may be encountered in severe illness, malnutrition, ( References range
recommended by the American Thyroid Association)
REFERENCE RANGE:
PREGNANCY Ultrasensitive TSH in uIU/mL
1st Trimester 0.100 – 2.500
2nd Trimester 0.200 – 3.000
3rd Trimester 0.300 – 3.000
Age Ultrasensitive TSH in uIU/mL
0 – 4 Days 1.00 - 39.00
2 Weeks to 5 Months 1.70 – 9.10
6 Months to 20 Yrs. 0.70 – 6.40
>55 Yrs. 0.50 - 8.90
*** End Of Report ***
This is an electronically authenticated report. Report printed date: 19-Mar-2025 02:45 PM,
Note: Assay results should be correlated clinically with other clinical findings and the total clinical status of the patient.
Page 7 of 7
